In VivoBiopharma Acquisitions Biopharma merger and acquisition value for the third quarter of 2022 reached $15.4bn from 41 transactions, 21 of which had disclosed values. Four M&A transactions hit or exceede
ScripAmgen, Inc. acknowledged during its business review on 8 February that drug pricing and competitive pressures are growing hurdles for the biopharmaceutical industry through the end of this decade. As
ScripThe biggest question going into the J.P. Morgan Healthcare Conference every year is which big company is going to announce a large acquisition. Amgen, Inc. CEO Robert Bradway’s answer on 11 January
In VivoThe biopharmaceutical sector did not relax in 2021. Biotechs raised record sums in private financing rounds and emerging companies went public with huge IPOs, while larger pharma players announced sev